ArticleGenome medicine2009
Postmenopausal estrogen and progestin effects on the serum proteome.
Article in Genome medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.Menopause (New York, N.Y.) · 2018Trial
- Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.The Lancet. Oncology · 2012Trial
- Plasma insulin-like growth Factor-Binding protein 7 predicts 20-Year Cancer-Specific and overall survival in ARIC.Journal of the National Cancer Institute · 2026Article
- Navigating the Proteomic Landscape of Menopause: A Review.Medicina (Kaunas, Lithuania) · 2024Review
- High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer.Archives of gynecology and obstetrics · 2024Article
- An Inflection Point in Cancer Protein Biomarkers: What was and What's Next.Molecular & cellular proteomics : MCP · 2023Article
- Long-term changes in plasma proteomic profiles in premenopausal and postmenopausal Black and White women: the Atherosclerosis Risk in Communities study.Menopause (New York, N.Y.) · 2022Article
- Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.Translational oncology · 2022Article
- Multimerin-1 and cancer: a review.Bioscience reports · 2022Review
- Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials.American journal of epidemiology · 2020Article
- Serum metabolomic profiles associated with postmenopausal hormone use.Metabolomics : Official journal of the Metabolomic Society · 2018Article
- Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.Biomarker research · 2017Article
- Augmented case-only designs for randomized clinical trials with failure time endpoints.Biometrics · 2016Article
- Plasma matrix metalloproteinase 2 levels and breast cancer risk.Cancer epidemiology · 2015Article
- Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.Seminars in reproductive medicine · 2014Review
- Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.Proteomics. Clinical applications · 2013Article
- Positive association between 25-hydroxyvitamin D and C-reactive protein is confounded by hormonal contraceptive use.Journal of women's health (2002) · 2013Article
- Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.Genome medicine · 2013Article
- Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.Cancer research · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWomen's Health Initiative randomized trials of postmenopausal hormone therapy reported intervention effects on several clinical outcomes, with some important differences between estrogen alone and estrogen plus progestin. The biologic mechanisms underlying these effects, and these differences, have yet to be fully elucidated.
methodsBaseline serum samples were compared with samples drawn 1 year later for 50 women assigned to active hormone therapy in both the estrogen-plus-progestin and estrogen-alone randomized trials, by applying an in-depth proteomic discovery platform to serum pools from 10 women per pool.
resultsIn total, 378 proteins were quantified in two or more of the 10 pooled serum comparisons, by using strict identification criteria. Of these, 169 (44.7%) showed evidence (nominal P < 0.05) of change in concentration between baseline and 1 year for one or both of estrogen-plus-progestin and estrogen-alone groups. Quantitative changes were highly correlated between the two hormone-therapy preparations. A total of 98 proteins had false discovery rates < 0.05 for change with estrogen plus progestin, compared with 94 for estrogen alone. Of these, 84 had false discovery rates <0.05 for both preparations. The observed changes included multiple proteins relevant to coagulation, inflammation, immune response, metabolism, cell adhesion, growth factors, and osteogenesis. Evidence of differential changes also was noted between the hormone preparations, with the strongest evidence in growth factor and inflammation pathways.
conclusionsSerum proteomic analyses yielded a large number of proteins similarly affected by estrogen plus progestin and by estrogen alone and identified some proteins and pathways that appear to be differentially affected between the two hormone preparations; this may explain their distinct clinical effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.